OncoSec Medical Inc (NASDAQ:ONCS) was down 5.3% during trading on Wednesday . The company traded as low as $1.79 and last traded at $1.80. Approximately 1,290,144 shares traded hands during trading, an increase of 41% from the average daily volume of 913,521 shares. The stock had previously closed at $1.90.
A number of equities research analysts recently commented on ONCS shares. ValuEngine lowered shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Maxim Group set a $5.00 price target on shares of OncoSec Medical and gave the company a “buy” rating in a report on Thursday, December 14th. HC Wainwright set a $6.00 price target on shares of OncoSec Medical and gave the company a “buy” rating in a report on Friday, December 15th. Finally, Piper Jaffray Companies assumed coverage on shares of OncoSec Medical in a report on Friday, February 9th. They set an “overweight” rating and a $4.00 price target for the company. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. OncoSec Medical has an average rating of “Buy” and a consensus price target of $5.00.
In related news, CEO Daniel J. O’connor acquired 16,667 shares of OncoSec Medical stock in a transaction on Monday, February 5th. The shares were acquired at an average cost of $1.50 per share, with a total value of $25,000.50. Following the transaction, the chief executive officer now owns 16,667 shares in the company, valued at $25,000.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 5.50% of the stock is currently owned by insiders.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.